Lifeboat Foundation

A study led by researchers at Sanford Burnham Prebys has found that in young women, certain genetic mutations are associated with treatment-resistant breast cancer. These mutations are not linked to treatment-resistant breast cancer in older women. The findings, published in the journal Science Advances, could help improve precision medicine and suggest a brand-new way of classifying breast cancer.

“It’s well established that as you get older, you’re more likely to develop cancer. But we’re finding that this may not be true for all cancers depending on a person’s genetic makeup,” says senior author Svasti Haricharan, Ph.D., an assistant professor at Sanford Burnham Prebys. “There may be completely different mechanisms driving cancer in younger and older people, which requires adjusting our view of aging and cancer.”

The research primarily focused on ER+/HER2-breast cancer, which is one of the most common forms of the disease. It is usually treated with hormonal therapies, but for some patients, these treatments don’t work. About 20% of tumors resist treatment from the very beginning, and up to 40% develop resistance over time.

Is the Executive Director of the Innovative Genomics Institute (https://innovativegenomics.org/people/brad-ringeisen/), an organization founded by Nobel Prize winner Dr. Jennifer Doudna, on the University of California, Berkeley campus, whose mission is to bridge revolutionary gene editing tool development to affordable and accessible solutions in human health and climate.

Dr. Ringeisen is a physical chemist with a Ph.D. from the University of Wisconsin-Madison, a Bachelor of Science in chemistry from Wake Forest University, a pioneer in the field of live cell printing, and an experienced administrator of scientific research and product development.

Continue reading “Dr. Brad Ringeisen, Ph.D. — Executive Director, Innovative Genomics Institute (IGI)” »

Ancient genomes can inform our understanding of the history of human adaptation through the direct tracking of changes in genetic variant frequency across different geographical locations and time periods. The authors review recent ancient DNA analyses of human, archaic hominin, pathogen, and domesticated animal and plant genomes, as well as the insights gained regarding past human evolution and behaviour.

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links:
Epigenetic Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
Use Code: CONQUERAGING

Continue reading “ApoB: Is Lower Always Better?” »

I’d place Sigmund et al. as one of my favorite papers that I have read this year! They leverage protein engineering to create genetically encoded nanocages which accumulate metals and appear as concentric circles when imaged by electron microscopy. Six classes of distinct “EMcapsulins” could be differentiated by training a machine learning model (a convolutional neural network) to recognize and classify them within images. Fusion of fluorescent protein domains to the EMcapsulins also allowed correlative imaging between fluorescence microscopy and electron microscopy. The authors demonstrated 3D imaging of EMcapsulins via serial section transmission electron microscopy and focused ion beam… More.

Multiplexable barcodes for electron microscopy are applied to brain imaging.

Year 2022 😗😁

Summary: A rare genetic mutation that causes blindness also appears to be associated with above-average intelligence, a new study reports.

Source: University of Leipzig

Continue reading “How a Gene Mutation Causes Higher Intelligence” »

The first gene therapy that can treat Duchenne muscular dystrophy (DMD) has been approved by the U.S. Food and Drug Administration; it will be marketed as Elevidys (delandistrogene moxeparvovec-rokl) by Sarepta Therapeutics Inc. Children aged four to five with the disorder and confirmed gene mutations will be eligible to receive the one-time treatment if insurers approve, as the cost is $3.2 million per patient.

DMD is caused by mutations in a gene called dystrophin, which results in a serious lack of functional dystrophin protein. The gene therapy works by sending a gene that can produce a shortened version of the dystrophin protein to patients; the company has termed it Elevidys micro-dystrophin.

Cardiovascular disease (CVD) is the leading cause of death worldwide and considered one of the most environmentally driven diseases. The role of DNA methylation in response to the individual exposure for the development and progression of CVD is still poorly understood and a synthesis of the evidence is lacking.

A systematic review of articles examining measurements of DNA cytosine methylation in CVD was conducted in accordance with PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. The search yielded 5,563 articles from PubMed and CENTRAL databases. From 99 studies with a total of 87,827 individuals eligible for analysis, a database was created combining all CpG-, gene-and study-related information. It contains 74,580 unique CpG sites, of which 1,452 CpG sites were mentioned in ≥ 2, and 441 CpG sites in ≥ 3 publications. Two sites were referenced in ≥ 6 publications: cg01656216 (near ZNF438) related to vascular disease and epigenetic age, and cg03636183 (near F2RL3) related to coronary heart disease, myocardial infarction, smoking and air pollution. Of 19,127 mapped genes, 5,807 were reported in ≥ 2 studies.

The technology could eventually revolutionize health care. We’ve seen CRISPR start to be used experimentally to treat children with cancer, for example. It is being explored for lots of genetic diseases. And last year, a company used CRISPR to try to treat a woman with dangerously high cholesterol.

But CRISPR could also transform farming, including aquaculture. This week, I wrote about researchers who inserted an alligator gene into catfish. The idea isn’t to make these fish more alligator-like, but to make them more resistant to disease. It turns out that alligators have a particular talent for fighting off infections.

These gene-edited fish, pigs, and other animals could soon be on the menu.

Continue reading “How CRISPR is making farmed animals bigger, stronger, and healthier” »